previous arrow
next arrow
Slider

Yourgene Health plc

(“Yourgene”, the “Company” or the “Group”)

Full-year Trading Update

Manchester, UK 8 April 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a trading update for the year ended 31 March 2019.

Trading Highlights

● Unaudited revenues were ahead of market expectations, increasing by 45% to over £8.9m (2018: £6.1m), with growth in all active regions
● Test volumes increased by 67% to over 82,000 (2018: 50,000)
● International revenues increased by 51% to £5.9m (2018: £3.9m), reflecting continued penetration of Middle Eastern and Asian markets plus growth in non-invasive prenatal screening (“NIPT”) and oncology research services delivered from Yourgene’s Taipei facility
● UK revenues increased by 20% to £1.2m (2018: £1.0m) from existing customers and Yourgene’s own service laboratory in Manchester
● Other European revenues grew by 47% to £1.8m (2018: £1.2m), from a broader network of customers than in the prior year● In the financial year, the Group generated sales from over 30 countries within Europe, the Middle East, Asia and Africa
● Cash at year end of £1.25m (31 March 2018: £0.28m) reflecting continued careful management of working capital
● The development of a version of the IONA® NIPT test for use on Illumina next-generation sequencing technology remains on course for launch in early 2020
● It is expected that results for the year ended 31 March 2019 will be released in July 2019

Lyn Rees, Chief Executive Officer of Yourgene, commented: “Since joining Yourgene in July 2018, we’ve made significant commercial progress in our existing markets as well as expanding our footprint to further new territories. We are also continuing to develop additional products and recently launched our Sage™ 32 plex test, a new higher throughput NIPT and analysis solution for clinical labs. We have redefined our relationships with Illumina and Thermo Fisher and we are now focused on the significant growth opportunity ahead of us, both within reproductive health and the wider genetic testing landscape.”

Adam Reynolds, Non-executive Chairman of Yourgene, commented: “Yourgene’s business has been transformed over the past financial year and I am delighted to see this being reflected in the Group’s trading performance. Our strengthened leadership team is now fully focused on driving the business into its next phase of growth.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:

 

Yourgene Health plc
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: +44 (0)161 667 1053

Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / James Caithie / Ludo Lazzaretti

Tel: +44 (0)20 7213 0880

finnCap (Broker)
Geoff Nash / Matthew Radley (Corporate Finance)
Tim Redfern / Sunila de Silva (ECM)

Tel: +44 (0)20 7220 0500

Vigo Communications
Ben Simons / Fiona Henson / Antonia Pollock
This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: +44 (0)20 7390 0234

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.

Yourgene Health’s first commercialised products are non-invasive prenatal tests (NIPT) for Down’s syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.

Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Yourgene Health’s customer-focused products and services support all types of customer, irrespective of size, geography and market maturity. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

  • 25 April 2019 - Completion of Acquisition +

    THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS DOCUMENT.

    Yourgene Health plc
    (“Yourgene” or the “Company”)

    Read More
  • 17 April 2019 - Proposed acquisition of Delta Diagnostics (UK) Limited +

    Yourgene Health plc
    (“Yourgene” or the “Company”)

    Proposed acquisition of Delta Diagnostics (UK) Limited ("Elucigene")
    and
    Proposed placing of a minimum of 92,682,928new Ordinary Shares
    and
    Proposed subscription for 4,878,048new Ordinary Shares

    Highlights

    ● Proposed acquisition of Elucigene, a leading molecular diagnostics manufacturer and developer, complementary to Yourgene’s current and planned product offering

    ●  Acquisition consideration of £9.2 million (comprising £6.3 million cash and £2.9 million equity), includes £0.4 million of net cash, representing an enterprise

    Read More
  • 8 April 2019 - Full-year Trading Update +

    Yourgene Health plc

    (“Yourgene”, the “Company” or the “Group”)

    Full-year Trading Update

    Manchester, UK 8 April 2019 : Yourgene Health (AIM : YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a trading update for the year ended 31 March 2019.

    Trading Highlights

    ●  Unaudited revenues were ahead of market expectations, increasing by 45% to over £8.9m (2018: £6.1m), with growth in all active regions
    ●  Test volumes increased by 67% to

    Read More
  • 25 March 2019 - Yourgene raises IONA® test awareness in Egypt with British Ambassador (2) +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Yourgene raises IONA® test awareness in Egypt with British Ambassador

    Manchester, UK 25 March 2019 : Yourgene Health ( AIM : YGEN ) , the international molecular diagnostics group which commercialises genetic products and services, has held an event in Egypt to raise awareness of the IONA® test, a non-invasive prenatal DNA test for Down’s syndrome, amongst the clinical community.

    The event was attended by His Excellency Sir Geoffrey Adams, the British

    Read More
  • 18 February 2019 - Yourgene Health Announces Capital and Commercial Restructuring with Major Shareholder +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Yourgene Health Announces Capital and Commercial Restructuring

    with Major Shareholder

    Manchester, UK – 18 February 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a restructuring of its financial and commercial relationship with Life Technologies Limited (“Life Technologies”).

    Lyn Rees, CEO of Yourgene Health, commented:

    “I am delighted with the restructuring of our relationship with Life Technologies, which places Yourgene

    Read More
  • 8 January 2019 - High throughput NIPT solution for clinical laboratories +

    Yourgene Health plc
    (“Yourgene”, the “Company”)
     
    Yourgene launches Sage™ 32 plex
     
    High throughput NIPT solution for clinical laboratories
     
    Manchester, UK – 8 January 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, is pleased to announce the launch of the Sage™ 32 plex test, a new high throughput non-invasive prenatal testing (“NIPT”) and analysis solution for clinical laboratories. 
     
    Sage™ 32 plex uses the latest
    Read More
  • 3 December 2018 - Half-year Results +

    yourgene health logo RGB

    Yourgene Health plc
    (“Yourgene”, the “Company” or the “Group”)

    Half-year Results

    Manchester, UK – 3 December 2018: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited half-year results for the six months ended 30 September 2018.

    Financial highlights

    •    Revenues increased by 45% to £3.9m (H1 2017-18: £2.7m)
    •    Gross profit up 49% to £2.0m (H1 2017-18: £1.3m)
    •    General administrative expenses down 4% to

    Read More
  • 7 November 2018 - Change of Name to Yourgene Health plc & Change of Website Address +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Change of Name to Yourgene Health plc
    &
    Change of Website Address

    Manchester, UK – 7 November 2018: Premaitha Health plc, the international molecular diagnostics group which commercialises genetic products and services that positively impact human health, is pleased to confirm the renaming of the Group as Yourgene Health plc (“Yourgene Health”).

    Further to the special resolution approved at the Group’s Annual General Meeting on 25 October 2018,

    Read More
  • 12 October 2018 - Trading Update & Notice of Results +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Trading Update & Notice of Results

    Manchester, UK – 12 October 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to provide an update on trading for the six-month period ended 30 September 2018 (“H1”).

    H1 revenues were approximately £3.9 million, an increase of 45 per cent over the corresponding period last year. The Company has made a strong start to the second

    Read More
  • 04 October 2018 - $1 million collaboration agreement +

    Premaitha Health PLC
    (“Premaitha,” the “Company” or the “Group”)

    $1 million collaboration agreement
    Partnership to provide genetic testing based on next generation sequencing for oncology

    Manchester, UK – 4 October 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces a new partnership agreement between the Group’s Yourgene Bioscience division (“Yourgene”) and a leading clinical research organisation in Taiwan (the “Partner”), to deliver next generation sequencing (“NGS”) testing in oncology.

    Under the terms of

    Read More
  • 28 September 2018 - Proposed fundraise to raise approximately £2.5 million +

    THIS ANNOUNCEMENT, INCLUDING THE APPENDIX AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

    Read More
  • 28 September 2018 - Full year results to 31 March 2018 and half-year trading update +

    Premaitha Health PLC
    (“Premaitha,” the “Company” or the “Group”)

    Full year results to 31 March 2018 and half-year trading update

    Manchester, UK – 28 September 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces its full year results for the twelve months ended 31 March 2018; and provides an update on trading in the current financial year to date.  

    Financial highlights

    Revenues increased by 100% to £6.15m (2017: £3.08m), including the first

    Read More
  • 20 September 2018 - Senior Commercial Appointment and Anticipated Directorate Change +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Senior Commercial Appointment and Anticipated Directorate Change

    Manchester, UK – 20 September 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the appointment of Mr Hayden Jeffreys to a senior commercial role within the Group and that he will be appointed to the Board as Group Commercial Director upon completion of the customary directorate appointment due diligence.

    Hayden has over 20

    Read More
  • 19 September 2018 - Legal Settlement and Licence Agreement with Illumina +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Legal Settlement and Licence Agreement with Illumina

    Manchester, UK – 19 September 2018: Premaitha Health plc (AIM: NIPT), a leading  international molecular diagnostics group, is pleased to announce that the Group has entered into a legal settlement and a licence and supply partnership agreement with Illumina Inc. (“Illumina”) (the “Agreements”), resolving the current non-invasive prenatal testing (“NIPT”) patent infringement litigation.  

    Key Terms of the Agreements

    ●  Premaitha

    Read More
  • 4 July 2018 - Board Changes +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Board Changes

    Manchester, UK – 4 July 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the appointment of Mr Lyn Rees as Chief Executive Officer and Mr Keng Hsu as Chief Operating Officer (Asia).  Dr Stephen Little, currently Chief Executive Officer, will move to the role of Executive Vice Chairman of the Group.

    Alan Chang, Non-executive Director, will step down

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Pregnant lady sitting at table with Laptop

Investor Relations
Ben Simons / Fiona Henson / Antonia Pollock
Vigo Communications
Sackville House
40 Piccadilly
London W1J 0DR
yourgene@vigocomms.com
T : +44 (0) 20 7390 0230

Two business people looking at computer screen